Highlights Magenta Therapeutics

Equities

MGTA

US55910K1088

Real-time Estimate Cboe BZX Other stock markets 03:03:41 2026-01-14 pm EST			5-day change	1st Jan Change
45.52 ^USD	+1.48%		+289.20%	+303.89%

23-09-11	Magenta Therapeutics, Inc.(NasdaqCM:MGTA) dropped from NASDAQ Composite Index	CI
23-09-10	Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	CI

Highlights

23-09-10	Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	CI
23-08-03	Magenta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-05-15	Magenta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
23-05-15	North American Morning Briefing : Hopes Build for -3-	DJ
23-05-02	Dianthus Therapeutics, Inc. entered into a definitive merger agreement to acquire Magenta Therapeutics, Inc. in a reverse merger transaction.	CI
23-04-06	Magenta Therapeutics, Inc. Enters into Sublease Termination and Release Agreement with Novartis Institutes for Biomedical Research, Inc	CI
23-02-03	North American Morning Briefing: Big Tech Disappointment to Drag on Nasdaq	DJ
23-01-26	North American Morning Briefing : Tech in Focus After Tesla Bounce; GDP Data Eyed	DJ
23-01-25	Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety	CI
22-12-20	Magenta Therapeutics Says it Stopped Group Four Dosing in MGTA-117 Trial; Shares Plunge	MT
22-12-20	Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial	CI
22-11-03	Magenta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
22-11-03	Magenta Therapeutics, Inc. to Present Data At the 2022 American Society of Hematology Annual Meeting	CI
22-08-26	North American Morning Briefing : Cautious Open -2-	DJ
22-08-04	Magenta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
22-05-16	Magenta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
22-04-14	Magenta Therapeutics to Focus Capital Spending on Leukemia Drug Trial, Cut Workforce by 14%	MT
22-04-14	Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway	CI
22-03-08	Magenta Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
22-03-08	Magenta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	CI
22-01-10	Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022	CI
21-12-14	Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning At the 2021 American Society of Hematology Annual Meeting	CI
21-11-04	Magenta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI
21-09-15	Magenta Therapeutics, Inc. Announces That Its Investigational New Drug Application for MGTA-117 Is Active with the U.S. Food and Drug Administration	CI
21-08-12	North American Morning Briefing : Stock Futures -3-	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Magenta Therapeutics

Equities

MGTA

US55910K1088

Highlights

Filters